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Summary Tirapazamine is a novel bioreductive agent with selective cytotoxicity against hypoxic tumour cells. Synergy with cisplatin and
other chemotherapeutic agents has been shown in preclinical trials. Pharmacokinetic studies of tirapazamine have revealed that exposure
increases with dose over the range of 18-450 mg m-2 for a single dose and of 9-390 mg m-2 for multiple doses. Plasma clearance is high.
Tirapazamine has been clinically tested in combination with cisplatin at escalating doses in a phase trial and at therapeutic doses in three
separate phase II trials in patients with advanced non-small-cell lung cancer (NSCLC) in 11 study centres. Limiting toxicity fortirapazamine at
an intravenous dose of 390 mg m-2 was acute, reversible hearing loss. Other frequently observed side-effects included muscle cramping and
gastrointestinal symptoms. Tirapazamine did not cause myelosuppression, and no toxic deaths were reported in these trials. The anti-tumour
efficacy against previously untreated, advanced NSCLC was evaluated by cumulative intent-to-treat analysis of 132 patients. The objective
response rate (confirmed by two independent measurements) was 25% [confidence interval (Cl) 17.8-33.33], with a median survival of 38.9
weeks (Cl 29.4-49.9). The efficacy of tirapazamine plus cisplatin shown in these trials was better than that of historical controls with cisplatin
monotherapy. Two large-scale international trials have been conducted, involving more than 70 centres, to confirm these results. The
CATAPULT trial compares tirapazamine plus cisplatin with cisplatin and has finished accrual with 446 patients. The CATAPULT II trial, which
is comparing tirapazamine plus cisplatin with etoposide plus cisplatin, had enrolled 550 patients by June 1997. Follow-up is ongoing.
Tirapazamine is the promising first drug from a new class of cytotoxic agents with a novel mechanism of action. It can be effectively combined
with cisplatin, and possibly with other agents, because of its safety profile and lack of overlapping dose-limiting toxicity, such as
myelosuppression. The combination of tirapazamine and cisplatin appears to be safe and effective in the treatment of NSCLC.
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Tirapazamine is the first agent belonging to a novel class of bio-
reductive cytotoxic drugs. It has a unique and selective mechanism
of action against hypoxic tumour cells; the lack of oxygen within
the cell results in tirapazamine's reduction to a toxic free radical
that induces single- and double-strength breaks in the tumour's
cellular DNA.
In preclinical in vivo models, tirapazamine has been shown to
have a broad spectrum of synergistic and additive anti-tumour
effects with many of the chemotherapeutic agents, such as the
platin compounds, including cisplatin, carboplatin (Dorie and
Brown, 1993) and oxaliplatin, alkylators, topoisomerase II
inhibitors, taxanes (Dorie and Brown, 1993), vinorelbine, vinblas-
tine, bleomycin, mitomycin-C, radiation therapy and cytokines
(IL-1, IL-2) (Graham et al, 1997). Cytotoxic effects increased two-
to five-fold in the mouse model when tirapazamine was given in
combination With cisplatin or cyclophosphamide. Potentiation of
the synergistic effect was seen if tirapazamine was given 1-3 h
before the cisplatin (Dorie and Brown, 1993). Resistance to tira-
pazamine is not easily induced, and it is not thought to be affected
by the recognized chemotherapy resistance mechanisms. A further
clinical benefit is that tirapazamine does not cause significant
myelosuppression.
PHARMACOKINETICS OF TIRAPAZAMINE
Pharmacokinetic studies with tirapazamine have shown that expo-
sure increases with dose over the range 18-450 mg m-2 for a single
dose and of 9-390 mg m-2 for multiple doses (Treat et al, 1997).
Oral bioavailability of more than 65% is seen with the drug.
Plasma clearance is high, at approximately 1 1 min-', with a
modest volume of distribution (approximately 60 1) and a short
half-life of about 40 min (range 20-58 min). Minimal accumula-
tion is seen with multiple dosing; steady state is reached with the
first dose and no change is seen in kinetics with time. There is no
difference in kinetics between men and women, and no kinetic
interactions have been observed in vivo with cisplatin or cyclo-
phosphamide. More than 70% of tirapazamine-related material is
eliminated in the urine, with less than 10% removed via the faeces.
The majority of the material is eliminated within 48 h.
CLINICAL TRIAL PROGRAMME
Phase I trials with tirapazamine and cisplatin in the treatment of
non-small-cell lung cancer (NSCLC) were initiated in November
1993 (Miller et al, 1997). Dose ranges for tirapazamine were 80-
390 mg m-2 and for cisplatin 75-100 mg m-2. The therapeutic dose
for tirapazamine was confirmed at 390 mg m-2 i.v. as a single dose.
Three phase II trials of cisplatin plus tirapazamine involving
11 trial centres in the USA have been completed, one using the dose
of 260 mg m-2 (Rodriguez et al, 1996) and two using the dose of
390 mg m-2 (Wozniak et al, 1996). The major eligibility criteria for
entry to these trials are shown in Table 1, and patient characteristics
in Table 2. Overall, a total of 132 patients with advanced NSCLC
were treated with doses of 260, 330 and 390 mg m-2 tirapazamine.
Afterprehydration and antiemetic support with both a 5-HT3 antag-
onist and dexamethasone, tirapazamine was infused for 2 h. After
an interval of 1 h, cisplatin at 75 mg m-2 was administered for I h,
followed by post-hydration and further antiemetic support.
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Table 1 Comparison of key eligibility criteria in the phase 11 cisplatin plus
tirapazamine NSCLC trials
007 007A 007B
Stage lIl orIV / I /
No brain metastases / / No symptoms
for > 30 days
Bidimensional disease / / /
PS
> 60% /
>70% /
Table 2 Patient characteristics in the phase 11 trials
Dose level
260 mg m-2 330 mg m-2 390 mg m-2 Total
(n = 52) (n = 10) (n = 70) (n = 132)
Gender
Male 25 (48) 9 (90) 43 (61) 77 (58)
Female 27 (52) 1 (10) 27 (39) 55 (42)
Stage
Regional 11 (21) 5 (50) 26 (37) 42 (32)
Distant 41 (79) 5 (50) 44 (63) 90 (68)
Histology
Squamous 11 (21) 2 (20) 25 (36) 38 (29)
NSQ 41 (79) 8 (80) 45 (64) 94 (71)
TLDH 17 (33) 3 (30) 18 (26) 38 (29)
NSQ, non-squamous cell carcinoma; 1LDH, LDH elevation (pathological).
Numbers in parentheses are percentages.
Acute, reversible hearing loss was found to be the dose-limiting
toxicity in the phase I trials, which occurred in all patients treated
at450 mg m-2 but only sporadically in those treated at doses below
this level. Hearing loss was fully reversible after a dose reduction
of 25% in the following cycles. In the phase II studies, 20% of
patients who received the dose of 390 mg m-2 experienced grade
1-3 ototoxicity. No grade IV, irreversible ototoxicity occurred
and, overall, hearing loss was experienced by 12.9% of patients.
Muscle cramps are another characteristic side-effect of tirapaza-
mine, usually seen 2-3 days after administration of the drug. For
this specific side-effect, grade 1-2 toxicity was predominantly
seen in these trials, and only 5.3% ofpatients had a level ofmuscle
cramps that met the World Health Organization criteria for grade 3
toxicity.
Other common side-effects associated with the administration
oftirapazamine plus cisplatin were nausea and vomiting, and 60%
of patients experienced this side-effect at grades 1-3. Thirty-six
per cent ofpatients were affected by diarrhoea, 30% by anorexia,
12% by tinnitus and 15% by alopecia. For all three phase II trials,
no treatment-related deaths have been reported to date, and no
significant myelosuppression has occurred.
For the efficacy assessments, cumulative intent-to-treat
analyses were undertaken. A conservative objective response defi-
nition required confirmation and an interval of6-8 weeks between
computerized tomography scans, as well as an independent review
of the response. The response rates for the phase II studies are
shown in Table 3. The cumulative response rate was 25% (CI
17.8-33.3%). A marked increase in efficacy, as well as increases
Table 3 Response rates for the evaluable patients of the combined phase 11
studies
Dose (mg m-2) Number of Number of Response Cl (%)
patients responders rate (%)
< 260 12 2 16.7 2.0-48.5
260 52 11 21.2 11.0-34.8
330 10 3 30.0 6.6-65.3
390 70 19 27.1 17.1-39.1
Total 132 33 25.0 17.8-33.3
Table 4 Efficacy of tirapazamine plus cisplatin in NSCLC compared with
cisplatin monotherapy
Study Treatment Rate (%) Median One-year
survival survival (%)
(months)
Historical (SWOG) Cisplatin 10 6 16
(n = 208) monotherapy
007 (II) Cisplatin plus 19 7 Too early
(n = 33) tirapazamine
(390 mg m-2)
007A (II) Cisplatin plus 23 9 33
(n = 48) tirapazamine
(260 mg m-2)
007B Cisplatin plus 30 12 > 40a
(n = 20) tirapazamine
(390 mg m-2)
aProjected.
in median survival and 1-year survival, were found with the
combination therapy ofcisplatin and tirapazamine, compared with
cisplatin as monotherapy (historical control dataonly) (Table 4). A
median survival time of 38.9 weeks (CI 29.4-49.9 weeks) was
seen for all patients and, for a patient population with predomi-
nantly stage IV disease, these are promising data.
To summarize the results ofthese phase II trials, consistent effi-
cacy was seen across the three studies, with a cumulative response
possibly occurring after several courses. The objective response
and survival rates were superior to those recently published for
cisplatin monotherapy and similar to those ofmodern platin-based
combinations. The combination of cisplatin and tirapazamine has
a good safety profile, with no toxic deaths or severe disabilities
resulting from treatment, reversible toxicity, no significant myelo-
suppression and minimal or no alopecia.
An international phase III programme was initiated in
December 1995 to confirm these results. The first trial, CATA-
PULT I, compares the efficacy of cisplatin monotherapy with that
of cisplatin plus tirapazamine; 446 patients have been enrolled in
the study. The first results will be available at the end of the year.
The second trial, CATAPULT II, compares cisplatin plus etoposide
with cisplatin plus tirapazamine; 550 patients were enrolled by
June 1997 and follow-up is ongoing. In addition to these large
phase III trials, further phase I/II trials are looking at triple-drug
combinations of tirapazamine plus cisplatin with one of the
following: vinorelbine, paclitaxel, etoposide, 5-fluorouracil or
radiation.
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CONCLUSIONS
Tirapazamine is a very promising new cytotoxic drug with a novel
mechanism of action. It can be combined effectively with
cisplatin, and possibly with other agents, because of its safety
profile and lack of overlapping dose-limiting toxicity, such as
myelosuppression. The combination of tirapazamine and cisplatin
appears to be safe and effective against NSCLC.
Potential future developments and uses for tirapazamine include
expansion of its primary indication, new drug combinations and
new disease indications, such as small-cell lung cancer. There is
also a place for including such effective combinations in a multi-
modality approach, such as with chemotherapy and radiation
therapy, or cytokines.
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